[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 35.175.200.4. Please contact the publisher to request reinstatement.
[Skip to Content Landing]

July 2019 - July 1959

Decade

Year

Issue

February 2015, Vol 72, No. 2, Pages 139-242

In This Issue of JAMA Neurology

Highlights

Abstract Full Text
free access
JAMA Neurol. 2015;72(2):139. doi:10.1001/jamaneurol.2014.2831
Viewpoint

Planning the Future of Neurology: Crisis or Opportunity

Abstract Full Text
JAMA Neurol. 2015;72(2):141-142. doi:10.1001/jamaneurol.2014.3448

This Viewpoint report that neurology has an opportunity to influence the integrated health care system as it adapts to an aging populace, as it develops a growing awareness of the burden of neurological disease, and as it assumes financial responsibility for large groups of patients.

Neuroinfectious Diseases: A Crisis in Neurology and a Call for Action

Abstract Full Text
JAMA Neurol. 2015;72(2):143-144. doi:10.1001/jamaneurol.2014.3442

This Viewpoint

Editorial

Is No Evidence of Disease Activity a Realistic Goal for Patients With Multiple Sclerosis?

Abstract Full Text
JAMA Neurol. 2015;72(2):145-147. doi:10.1001/jamaneurol.2014.3860

Moving Targets for Hematopoietic Stem Cell Transplantation for Multiple Sclerosis

Abstract Full Text
JAMA Neurol. 2015;72(2):147-149. doi:10.1001/jamaneurol.2014.3831

Challenges and Opportunities in Linking Brain-Based Biomarkers to Person-Specific Variation in Cognition: Pumping Up the Volume

Abstract Full Text
JAMA Neurol. 2015;72(2):149-151. doi:10.1001/jamaneurol.2014.3832
Original Investigation

Evaluation of No Evidence of Disease Activity in a 7-Year Longitudinal Multiple Sclerosis Cohort

Abstract Full Text
free access has audio
JAMA Neurol. 2015;72(2):152-158. doi:10.1001/jamaneurol.2014.3537

This cohort study found that no evidence of disease activity is difficult to sustain long term even with treatment.

Clinical Trial

High-Dose Immunosuppressive Therapy and Autologous Hematopoietic Cell Transplantation for Relapsing-Remitting Multiple Sclerosis (HALT-MS): A 3-Year Interim Report

Abstract Full Text
free access
JAMA Neurol. 2015;72(2):159-169. doi:10.1001/jamaneurol.2014.3780

This 3-year interim analysis of a phase 2 clinical trial shows that high-dose immunosuppressive therapy with autologous hematopoietic cell transplantation is effective for inducing sustained remission of active relapsing-remitting multiple sclerosis.

Association of 3.0-T Brain Magnetic Resonance Imaging Biomarkers With Cognitive Function in the Dallas Heart Study

Abstract Full Text
free access
JAMA Neurol. 2015;72(2):170-175. doi:10.1001/jamaneurol.2014.3418

This whole-brain 2-dimensional FLAIR and 3-dimensional MPRAGE MR imaging study finds that brain MR imaging volumes may be important early biomarkers of risk for cognitive insult in a young, multiracial/multiethnic population. See the Editorial by Hedden.

Association of Cerebrospinal Fluid Levels of Lateral Olfactory Tract Usher Substance (LOTUS) With Disease Activity in Multiple Sclerosis

Abstract Full Text
free access
JAMA Neurol. 2015;72(2):176-179. doi:10.1001/jamaneurol.2014.3613

This original investigation reports that lateral olfactory tract usher substance concentration may be useful as a possible biomarker for multiple sclerosis and that low lateral olfactory tract usher substance concentrations may be possibly involved in Nogo receptor-1 signaling, which may induce axonal degeneration in the relapse phase of relapsing-remitting multiple sclerosis and secondary progressive multiple sclerosis.

Investigations on CXCL13 in Anti–N-Methyl-D-Aspartate Receptor Encephalitis: A Potential Biomarker of Treatment Response

Abstract Full Text
free access
JAMA Neurol. 2015;72(2):180-186. doi:10.1001/jamaneurol.2014.2956

This retrospective cohort study reports that C-X-C motif chemokine 13 is a potentially useful biomarker of treatment response and outcome in Anti–N-methyl-D-aspartate receptor encephalitis.

Antibodies to Aquaporin 4, Myelin-Oligodendrocyte Glycoprotein, and the Glycine Receptor α1 Subunit in Patients With Isolated Optic Neuritis

Abstract Full Text
free access
JAMA Neurol. 2015;72(2):187-193. doi:10.1001/jamaneurol.2014.3602

This case-control study of isolated optic neuritis (ON) finds that nearly half of the patients with ON had antibodies to aquaporin 4, myelin-oligodendrocyte glycoprotein, and/or the α1 subunit of the glycine receptor.

Frequency of Cholinergic and Caudate Nucleus Dopaminergic Deficits Across the Predemented Cognitive Spectrum of Parkinson Disease and Evidence of Interaction Effects

Abstract Full Text
free access
JAMA Neurol. 2015;72(2):194-200. doi:10.1001/jamaneurol.2014.2757

This cross-sectional study reports that cortical cholinergic denervation is a major neurodegeneration associated with progressive declines across the spectrum of cognitive impairment in PD and typically occurs in the context of significant caudate nucleus dopaminergic denervation. Findings indicate dopaminergic and cholinergic degenerations exhibit both independent and interactive contributions to cognitive impairment in PD.

Evolution of Prodromal Clinical Markers of Parkinson Disease in a GBA Mutation–Positive Cohort

Abstract Full Text
free access
JAMA Neurol. 2015;72(2):201-208. doi:10.1001/jamaneurol.2014.2950

This clinic-based 2-year follow-up study reports that, as a group, GBA mutation–positive individuals show a deterioration in clinical markers consistent with the prodrome of Parkinson disease. Within this group of individual, 10% appear to be evolving at a more rapid rate.

Rarity of the Alzheimer Disease–Protective APP A673T Variant in the United States

Abstract Full Text
free access
JAMA Neurol. 2015;72(2):209-216. doi:10.1001/jamaneurol.2014.2157

This case-control study examines the frequency of the A673T variant in the amyloid precursor protein gene (APP) in the United States and Sweden to determine whether it will significantly contribute to risk assessment for Alzheimer disease.

Case Report/Case Series

A Rare Cause of Radiculomyelitis: Dural Arteriovenous Fistula

Abstract Full Text
free access
JAMA Neurol. 2015;72(2):217-218. doi:10.1001/jamaneurol.2014.2077

This case report finds that despite adequate medical treatment of myelitis, if slow progression is seen in the follow-up clinically and radiologically, dural arteriovenous fistulas should be kept in mind in the etiopathogenesis.

Massive CAG Repeat Expansion and Somatic Instability in Maternally Transmitted Infantile Spinocerebellar Ataxia Type 7

Abstract Full Text
free access
JAMA Neurol. 2015;72(2):219-223. doi:10.1001/jamaneurol.2014.1902

This case report finds that infantile SCA7, which is often paternally transmitted, can rarely arise by maternal transmission, which has implications for diagnosis and counseling among families of patients with SCA7.

Posterior Cortical Atrophy as an Extreme Phenotype of GRN Mutations

Abstract Full Text
free access
JAMA Neurol. 2015;72(2):224-228. doi:10.1001/jamaneurol.2014.3308

This report of a case of posterior cortical atrophy (PCA) with GRN mutations finds that analysis of the GRN gene should be performed in patients with PCA.

Special Communication

Implementing a Mobile Stroke Unit Program in the United States: Why, How, and How Much?

Abstract Full Text
JAMA Neurol. 2015;72(2):229-234. doi:10.1001/jamaneurol.2014.3618

This review discusses the feasibility and use of a mobile stroke unit for patients with ischemic and hemorrhagic stroke.

Clinical Implications of Basic Neuroscience Research

Role of Endogenous Neural Stem Cells in Spinal Cord Injury and Repair

Abstract Full Text
free access
JAMA Neurol. 2015;72(2):235-237. doi:10.1001/jamaneurol.2014.2927

This brief review describes the beneficial functions of endogenous neural stem cells after spinal cord injury.

Comment & Response

Multiple Sclerosis and Alcohol Misuse

Abstract Full Text
JAMA Neurol. 2015;72(2):238. doi:10.1001/jamaneurol.2014.3876

Multiple Sclerosis and Alcohol Misuse—Reply

Abstract Full Text
JAMA Neurol. 2015;72(2):238. doi:10.1001/jamaneurol.2014.3879

Autosomal Recessive Cerebellar Ataxia 3 Due to Homozygote c.132dupA Mutation Within the ANO10 Gene

Abstract Full Text
JAMA Neurol. 2015;72(2):238-239. doi:10.1001/jamaneurol.2014.3918

Autosomal Recessive Cerebellar Ataxia 3 Due to Homozygote c.132dupA Mutation Within the ANO10 Gene—Reply

Abstract Full Text
JAMA Neurol. 2015;72(2):239. doi:10.1001/jamaneurol.2014.3921

Statins and Intracerebral Hemorrhage

Abstract Full Text
JAMA Neurol. 2015;72(2):240. doi:10.1001/jamaneurol.2014.4171

Statins and Intracerebral Hemorrhage—Reply

Abstract Full Text
JAMA Neurol. 2015;72(2):240-241. doi:10.1001/jamaneurol.2014.4174
Book and Media Review

Review of The Comatose Patient

Abstract Full Text
JAMA Neurol. 2015;72(2):242. doi:10.1001/jamaneurol.2014.3984
JAMA Neurology Masthead

JAMA Neurology

Abstract Full Text
free access
JAMA Neurol. 2015;72(2):140. doi:10.1001/jamaneurol.2014.2832
×